Restructuring On The Table For FibroGen After Roxadustat Rejection

As anticipated, the FDA issued a complete response letter for roxadustat. While the drug is expected to win EU approval, it is unclear if FibroGen and AstraZeneca will be willing to fund another trial.

Malekidneys-cancer
The FDA issued a complete response letter for FibroGen and AstraZeneca's roxadustat in anemia of chronic kidney disease • Source: Shutterstock

With the US Food and Drug Administration rejecting FibroGen, Inc./AstraZeneca PLC’s roxadustat for anemia in chronic kidney disease (CKD), as expected, FibroGen may be forced to restructure, shifting its attention to Phase III pipeline asset pamrevlumab if the partners choose not to conduct a new clinical trial that could support US approval. Meanwhile, the drug’s setback could create an opening for competitors, particularly GlaxoSmithKline plc’s daprodustat and Akebia Therapeutics, Inc.’s vadadustat.

San Francisco-based FibroGen said 11 August that the FDA issued a complete response letter (CRL), requesting the company and AstraZeneca...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.